I guess sooner or later interview will be released for us to know what lies ahead.
It is interesting to note that although ANN only speaks of Dr Sud stepping down his non-exec role, it doesn't specify that he is also resigning from Chief Medical Officer role - but we can infer he is stepping down both roles from his comment. "It is with some sadness that I move on from IHL and I wish the company success in it’s future drug development plans.”
Then CMO role becomes vacant but I surmise that the title has changed now to Chief Technology Officer and given to Mr Lekhram Changoer. Slight term deviations like this could have been better explained.
I hope more clarification comes in sooner than later as people don't like uncertainties and there are two more days of tax selling left.
Reminding ourselves yet again who Mr Changoer is: Lekhram Changoer, MSc Co-founder and COO Mr. Changoer is responsible for the Company’s R&D, clinical & product development, commercial operations, quality assurance and Sales & Marketing of technical, consumer healthcare and pharmaceutical products. He has co-developed several patents in the cannabinoid field. Previously, he was CTO and Co-founder of AXIM Biotechnologies, driving market capitalization to over US$ 1.2B.
IHL Price at posting:
24.0¢ Sentiment: Hold Disclosure: Held